Remove core-values-1
article thumbnail

Strategies for Combination Therapy in Oncology: Part Two – Working with the “Status Quo”

PM360

Status Quo: The Core Issue In oncology, it has been the “status quo” for combination therapies to face challenges with respect to pricing and access. Present approaches for value assessment and pricing are designed for monotherapy agents and lack the capacity to capture the value and facilitate sustainable pricing of combinations.

article thumbnail

Announcing changes to the 2023 Journal Citation Reports

Clarivate

Starting from the 2023 JCR release, Journal Impact Factors will be expanded to all Web of Science Core Collection journals including arts and humanities. Today we’re proud to announce that in the 2023 release of the Journal Citation Reports , all Web of Science Core Collection journals will receive a Journal Impact Factor (JIF).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

How the Web of Science enables innovation in agriculture

Clarivate

The tool uses APIs (Application Programming Interfaces) and, among them, the Web of Science API to make sure publications are peer-reviewed and indexed in the Web of Science Core Collection. The Web of Science API has recently processed more than 2,500 articles during quality assurance of the CGIAR Annual Performance Report. Contact us today.

article thumbnail

Getting the Full Picture: Institutional unification in the Web of Science

Clarivate

of Fisheries & Oceans”, “Department of Fisheries and Oceans”, “Department of Fisheries and Oceans Canada (DFO)” and many more, including the “Bedford Institute,” which at face value indicates no relationship to the parent institution. For this organization, author affiliations listed in the original, published papers include “Canada Dept.

article thumbnail

Sanofi signs deal to buy Provention Bio for $2.9bn

Pharmaceutical Technology

Sanofi has signed an agreement to buy US-based biopharmaceutical firm Provention Bio in a deal valued at nearly $2.9bn. With the acquisition, Sanofi will add a fully owned, first-in-class, disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D), Tzield, to its core asset portfolio in General Medicines.

article thumbnail

7 strategies to avoid the commoditization in the MedTech business

Cesare Ferrari

Every company must find its way of countering commoditization’s power, exploiting market knowledge and core competencies. Developing operational excellence can create value by offering the customers a cheaper product made possible through efficiency and cost reductions. 1 Moving across To move across, a company can: 1.

article thumbnail

Ethical Sales Practices Are Driven By These Business Principles

Integrity Solutions

But while a sizable number of Fortune 500 companies claim “integrity” as one of their core values, in reality it remains conceptual. Clearly, how (and whether) companies deliver on that core value promise varies dramatically. According to the 2021 Global Business Ethics Survey® , around 1 in 5 U.S.

Ethics 52